|
2015 Conference Publication ANALYSING THE EVIDENCE - THE STATISTICS OF SMALL NUMBERSMartin, Andrew (2015). ANALYSING THE EVIDENCE - THE STATISTICS OF SMALL NUMBERS. HOBOKEN: WILEY-BLACKWELL. |
|
2015 Conference Publication RANDOMISED PHASE 3 TRIAL OF THE ADDITION OF MITOMYCIN TO BCG AS ADJUVANT INTRAVESICAL THERAPY FOR HIGH-RISK, NON-MUSCLE-INVASIVE BLADDER CANCER(ANZUP 1301)Chalasani, Venu, Sengupta, Shomik, Stockler, Martin, McCombie, Steve, Hawks, Cynthia, Krieger, Laurence, Anderson, Paul, Grummet, Jeremy, Mitterdorfer, Andrew J., Bishop, Conrad, Beardsley, Emma, Martin, Andrew, Lawrence, Nicola, Wong, Nicole, Chan, Howard, Pysarenko, Mariya, Harper, Matthew, Patel, Manish, Hamid, Akil, Davis, Ian and Hayne, Dickon (2015). RANDOMISED PHASE 3 TRIAL OF THE ADDITION OF MITOMYCIN TO BCG AS ADJUVANT INTRAVESICAL THERAPY FOR HIGH-RISK, NON-MUSCLE-INVASIVE BLADDER CANCER(ANZUP 1301). HOBOKEN: WILEY-BLACKWELL. |
|
2015 Conference Publication RANDOMISED PHASE 3 TRIAL OF ENZALUTAMIDE IN ANDROGEN DEPRIVATION THERAPY WITH RADIATION THERAPY FOR HIGH RISK, CLINICALLY LOCALISED, PROSTATE CANCER: ENZARAD (ANZUP 1303)Williams, Scott G., Davis, Ian D., Sweeney, Christopher, Stockler, Martin R., Martin, Andrew, Hague, Wendy, Coskinas, Xanthi, Long, Anne, Yip, Sonia, Tu, Emily, Chan, Howard, Lawrence, Nicky, McDermott, Ray, Hughes, Simon, Marchesin, Vittorio, Deignan, Olwyn and Nguyen, Paul L. (2015). RANDOMISED PHASE 3 TRIAL OF ENZALUTAMIDE IN ANDROGEN DEPRIVATION THERAPY WITH RADIATION THERAPY FOR HIGH RISK, CLINICALLY LOCALISED, PROSTATE CANCER: ENZARAD (ANZUP 1303). HOBOKEN: WILEY-BLACKWELL. |
|
2015 Conference Publication RANDOMISED PHASE 3 TRIAL OF ENZALUTAMIDE IN FIRST LINE ANDROGEN DEPRIVATION THERAPY FOR METASTATIC PROSTATE CANCER: THE ANZUP ENZAMET TRIAL (ANZUP 1304)Davis, Ian, Stockler, Martin, Martin, Andrew, Hague, Wendy, Coskinas, Xanthi, Yip, Sonia, Dazo, Carlo, Long, Anne, Lawrence, Nicky, Chan, Howard, McDermott, Ray, Chowdhury, Simon, Marchesin, Vittorio, Deignan, Olwyn, Parulekar, Wendy, Suris, Alexander Montenegro and Sweeney, Christopher (2015). RANDOMISED PHASE 3 TRIAL OF ENZALUTAMIDE IN FIRST LINE ANDROGEN DEPRIVATION THERAPY FOR METASTATIC PROSTATE CANCER: THE ANZUP ENZAMET TRIAL (ANZUP 1304). HOBOKEN: WILEY-BLACKWELL. |
|
2015 Conference Publication RANDOMISED PHASE 3 DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF METHOXYFLURANE WITH PERIPROSTATIC LOCAL ANAESTHESIA TO REDUCE THE DISCOMFORT OF TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BIOPSY (PAIN-FREE TRUS B): ANZUP 1501Grummet, Jeremy, Davis, Ian, Martin, Andrew, Buchan, Nicholas, Chalasani, Venu, Frydenberg, Mark, Hayne, Dickon, Lalak, Andre, Patel, Manish, Williams, Andrew, Woo, Henry, Lawrence, Nicola, Chan, Howard, Bishop, Claudia, Wong, Nicole, Coskinas, Xanthi and Stockler, Martin (2015). RANDOMISED PHASE 3 DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF METHOXYFLURANE WITH PERIPROSTATIC LOCAL ANAESTHESIA TO REDUCE THE DISCOMFORT OF TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BIOPSY (PAIN-FREE TRUS B): ANZUP 1501. HOBOKEN: WILEY-BLACKWELL. |
|
2015 Conference Publication Discussing and prescribing expensive unfunded anticancer drugs in AustraliaKarikios, D., Mileshkin, L., Martin, A., Ferraro, D. and Stockler, M. (2015). Discussing and prescribing expensive unfunded anticancer drugs in Australia. European Cancer Congress, Vienna Austria, 2015. OXFORD: ELSEVIER SCI LTD. doi: 10.1016/S0959-8049(16)30506-8 |
|
2015 Conference Publication A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours: the P3BEP Trial (Anzup 1302)Lawrence, Nicola, Toner, Guy, Martin, Andrew, Stockler, Martin, Yeung, Annie, Wong, Nicole, Thomson, Damien, Gebski, Val, Yip, Sonia, King, Madeleine, Friedlander, Michael, Quinn, David, Tan, Thean Hsiang, Chan, Howard, Hanning, Fritha, Weickhardt, Andrew, Jeffery, Mark, Stevanovic, Amanda, Hovey, Elizabeth, Wyld, David, Davis, Ian and Grimison, Peter (2015). A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours: the P3BEP Trial (Anzup 1302). COSA’s 42nd Annual Scientific Meeting. Rare Cancers: Common Goals, Hobart, Australia, 17–19 November 2015. Chichester, United Kingdom: Wiley-Blackwell. doi: 10.1111/ajco.12432_2 |
|
2014 Conference Publication THE PROCARE TRIAL: A PHASE II RANDOMISED CONTROLLED TRIAL OF SHARED CARE FOR FOLLOW-UP OF MEN WITH PROSTATE CANCEREmery, Jon, Schofield, Penny, Jefford, Michael, King, Madeleine, Pirotta, Marie, Hayne, Dickon, Martin, Andrew, Trevena, Lyndal, Lim, Tee and Constable, Roger (2014). THE PROCARE TRIAL: A PHASE II RANDOMISED CONTROLLED TRIAL OF SHARED CARE FOR FOLLOW-UP OF MEN WITH PROSTATE CANCER. HOBOKEN: WILEY-BLACKWELL. |
|
2014 Conference Publication The use of 3-dimensional ultrasound of the pelvic floor to predict recurrence risk after pelvic reconstructive surgeryRodrigo, Natassia, Wong, Vivien, Shek, Ka Lai, Martin, Andrew and Dietz, Hans Peter (2014). The use of 3-dimensional ultrasound of the pelvic floor to predict recurrence risk after pelvic reconstructive surgery. Blackwell Publishing. doi: 10.1111/ajo.12171 |
|
2012 Conference Publication Usefulness of medical oncologists' estimates of survival time in people with advanced cancerKiely, Belinda E., Martin, Andrew J., Tattersall, Martin H. N., Nowak, Anna K., Goldstein, David, Wilcken, Nicholas, Wyld, David, Beale, Philip James, Jefford, Michael, Glasgow, Amanda L., Abdi, Ehtesham A., Glare, Paul A. and Stockler, Martin R. (2012). Usefulness of medical oncologists' estimates of survival time in people with advanced cancer. 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL USA, 1-6 June 2012. Alexandria, VA USA: American Society of Clinical Oncology. |
